Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995128 | 0.92 | PIM2 (0.55) | PIM2PIM1CSNK2A2CSNK2A1BRAF | |
| SCHEMBL4997022 | 0.89 | CHEK1 (0.51) | PIM2PIM1CSNK2A2CSNK2A1FYN | |
| SCHEMBL5003418 | 0.87 | CHEK1 (0.55) | PIM2CHEK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5002971 | 0.87 | PIM2 (0.50) | PIM2PIM1CSNK2A2CSNK2A1BRAF | |
| SCHEMBL4996178 | 0.86 | PIM2 (0.52) | PIM2PIM1CSNK2A2CSNK2A1FYN | |
| SCHEMBL4994141 | 0.85 | POLB (0.55) | PIM2PIM1CSNK2A2CSNK2A1SMN1; SMN2 | |
| SCHEMBL5003109 | 0.85 | ALDH1A1 (0.55) | PIM2PIM1CSNK2A2CSNK2A1FYN | |
| SCHEMBL5003195 | 0.84 | PIM2 (0.50) | PIM2PIM1CSNK2A2CSNK2A1BRAF | |
| SCHEMBL4997496 | 0.84 | MAPT (0.51) | PIM2PIM1CSNK2A2CSNK2A1BRAF | |
| SCHEMBL4997813 | 0.83 | PIK3CA (0.55) | PIM2PIM1CSNK2A2CSNK2A1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | PIM2 1679/4885PIM1 1047/4885CSNK2A2 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.